And if you do need to stop taking the medication for any reason, they may help protect against some of the potential weight regain
Inside the case study: Where GLP-1 persistence declines in real-world programs, and why traditional metrics miss it Why reminder-based adherence models are insufficient for long-term metabolic care How to address behavioral and emotional risk moments at scale without increasing compliance burden What a scalable, brand-ready DTP persistence architecture looks like across markets
Understanding Semaglutide Semaglutide is an FDA-approved GLP-1 receptor agonist effective for long-term weight management in adults with obesity or those overweight with a related health condition
See also: GLP-1 Guides | Provider Comparisons Search and AI answer brief Practical answer: Retatrutide and Gastroparesis Risk: What to Expect and How to Manage Retatrutide can cause gastroparesis as a side effect, but it is usually temporary and manageable
Meanwhile, a comparable study in the United States showed that around 60% of participants supported the idea of classifying obesity as a disease (Puhl and Liu, 2015)
